Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
The U.S. FDA has approved Lyumjev™ (insulin lispro-aabc injection) from Eli Lilly (NYSE: LLY), a rapid-acting insulin for adults with type 1 and type 2 diabetes. Lyumjev enhances glycemic control by mimicking natural insulin absorption, effectively reducing post-meal blood sugar spikes. The approval is based on Phase 3 studies, PRONTO-T1D and PRONTO-T2D, showing that Lyumjev outperforms Humalog in lowering A1C levels at 26 weeks. Lyumjev will be priced similarly to Humalog and is part of the Lilly Insulin Value Program, allowing affordable access to patients.
Eli Lilly and Company (NYSE: LLY) initiated a Phase 3 trial to assess the efficacy and safety of baricitinib in hospitalized adults with COVID-19. This randomized, double-blind, placebo-controlled study aims to enroll 400 patients across the U.S., Europe, and Latin America. Key endpoints include mortality rates and the requirement for mechanical ventilation by Day 28. Baricitinib is currently approved for rheumatoid arthritis and may mitigate COVID-19 complications by reducing hyperinflammation. Results are anticipated in the coming months as Lilly combats the pandemic and supports ongoing related research.
On June 13, 2020, Eli Lilly (NYSE: LLY) announced that Trulicity® (dulaglutide) exhibited significantly higher adherence and persistence compared to semaglutide and exenatide in type 2 diabetes patients. Presented at the ADA's 80th Scientific Sessions, the study utilized U.S. claims data, showing that after six months, 59.7% of Trulicity users adhered to treatment, compared to 42.7% for semaglutide and 58.1% versus 40.3% for exenatide. Moreover, treatment discontinuation rates were lower for Trulicity at 30.8%, compared to 40.8% and 32.1% for its competitors.